MARINUS PHARMACEUTICALS INC (MRNS) Stock Price & Overview
NASDAQ:MRNS • US56854Q2003
Current stock price
The current stock price of MRNS is 0.55 USD. Today MRNS is up by 0.09%. In the past month the price increased by 2.42%. In the past year, price decreased by -94.48%.
MRNS Key Statistics
- Market Cap
- 30.371M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.44
- Dividend Yield
- N/A
MRNS Stock Performance
MRNS Stock Chart
MRNS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MRNS. When comparing the yearly performance of all stocks, MRNS is a bad performer in the overall market: 72.37% of all stocks are doing better.
MRNS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MRNS. MRNS has a bad profitability rating. Also its financial health evaluation is rather negative.
MRNS Earnings
On November 12, 2024 MRNS reported an EPS of -0.42 and a revenue of 8.54M. The company missed EPS expectations (-0.53% surprise) and missed revenue expectations (-11.09% surprise).
MRNS Forecast & Estimates
13 analysts have analysed MRNS and the average price target is 1.09 USD. This implies a price increase of 97.82% is expected in the next year compared to the current price of 0.55.
For the next year, analysts expect an EPS growth of 19.91% and a revenue growth 9.81% for MRNS
MRNS Groups
Sector & Classification
MRNS Financial Highlights
Over the last trailing twelve months MRNS reported a non-GAAP Earnings per Share(EPS) of -2.44. The EPS increased by 7.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -220.81% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MRNS Ownership
MRNS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.12 | 846.194B | ||
| JNJ | JOHNSON & JOHNSON | 20.64 | 576.236B | ||
| MRK | MERCK & CO. INC. | 23.12 | 294.041B | ||
| PFE | PFIZER INC | 9.06 | 156.828B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.24 | 121.027B | ||
| ZTS | ZOETIS INC | 16.01 | 49.233B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.97 | 27.078B | ||
| VTRS | VIATRIS INC | 5.2 | 15.394B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.99 | 12.22B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.402B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.647B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.596B | ||
| CORT | CORCEPT THERAPEUTICS INC | 45.51 | 4.098B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MRNS
Company Profile
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 165 full-time employees. The company went IPO on 2014-07-31. The firm is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The firm is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). The company is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
Company Info
IPO: 2014-07-31
MARINUS PHARMACEUTICALS INC
5 Radnor Corporate Center Suite 500, 100 Matsonford Rd
Radnor PENNSYLVANIA 19087 US
CEO: Scott Braunstein
Employees: 165
Phone: 14848014670
MARINUS PHARMACEUTICALS INC / MRNS FAQ
Can you describe the business of MARINUS PHARMACEUTICALS INC?
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 165 full-time employees. The company went IPO on 2014-07-31. The firm is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The firm is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). The company is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
Can you provide the latest stock price for MARINUS PHARMACEUTICALS INC?
The current stock price of MRNS is 0.55 USD. The price increased by 0.09% in the last trading session.
Does MARINUS PHARMACEUTICALS INC pay dividends?
MRNS does not pay a dividend.
What is the ChartMill technical and fundamental rating of MRNS stock?
MRNS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists MRNS stock?
MRNS stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of MARINUS PHARMACEUTICALS INC (MRNS)?
MARINUS PHARMACEUTICALS INC (MRNS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.44).
How many employees does MARINUS PHARMACEUTICALS INC have?
MARINUS PHARMACEUTICALS INC (MRNS) currently has 165 employees.